By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nerviano Medical Sciences (NervianoMS) 

Viale Pasteur, 10

Milano    20014  Italy
Phone: 39-0331-58-1111 Fax:



Company News
Ignyta (RXDX) Announces Amendment To License Agreement With Nerviano Medical Sciences (NervianoMS) 12/15/2014 10:14:02 AM
Ignyta (RXDX) And Nerviano Medical Sciences (NervianoMS) Announce License Agreement For Two First-in-Class Kinase Inhibitors 8/5/2014 10:28:01 AM
Cellectis And Accelera (Nerviano Medical Sciences (NervianoMS)) Sign An Agreement To Complete Preclinical Studies Of Cellectis’ Lead Product Candidate UCART19 6/5/2014 12:47:32 PM
Nerviano Medical Sciences (NervianoMS) and Servier Announce a Collaboration and License Agreement for a Novel Anticancer Drug 7/30/2013 9:26:41 AM
Professor Carlo Maria Croce Joins the Board of Nerviano Medical Sciences (NervianoMS) 10/26/2011 10:59:06 AM
Nerviano Medical Sciences (NervianoMS) Announces New License Agreement 3/15/2011 8:56:23 AM
Nerviano Medical Sciences (NervianoMS) Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor 5/13/2009 8:38:22 AM
ChemDiv, Inc. Successful Milestone In Lead Discovery Collaboration With Nerviano Medical Sciences (NervianoMS) 3/2/2009 12:13:48 PM
Nerviano Medical Sciences (NervianoMS) Release: FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers 2/10/2009 10:48:16 AM
Nerviano Medical Sciences (NervianoMS) Announces a New Collaboration Agreement With Genentech, Inc. (DNA) (JOBS) to Discover Antibody Drug Conjugates 10/21/2008 6:39:16 AM